Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway

Yuelai Zhou*
Jinlong Hu*

*These 2 authors contributed equally to this work

Corresponding Author: Yuelai Zhou, e-mail: yuelaizhou32@hotmail.com

Source of support: Departmental sources

Background: Osteosarcoma is a prevalent type of bone tumor mainly reported in children and adolescents. The treatments for osteosarcoma are limited and are associated with serious adverse effects. In this study we evaluated the anticancer activity of Evodiamine, a plant-derived natural product, against a panel of osteosarcoma cells and explored the underlying mechanisms.

Material/Methods: The viability of osteosarcoma cell lines was investigated by MTT assay. Apoptosis was detected by DAPI and annexin V/PI staining and cell cycle analysis was performed by flow cytometry. The expression of the proteins was examined by Western blotting.

Results: The results of the present study indicated that Evodiamine inhibited the proliferation of U2OS osteosarcoma cells with an IC₅₀ of 6 µM. Further investigations indicated the antiproliferative effects of Evodiamine are due to induction of apoptosis and G2/M cell cycle arrest. The results of Western blotting revealed that the expression of several apoptosis (Cytochrome c, Bax, Bid, Caspase 3, 9, 8, and PARP) and cell cycle-related proteins (cyclin B1, Cdc25c, and Cdc2) was significantly altered. Evodiamine also suppressed the migration and invasion of U2OS osteosarcoma cells. Moreover, Evodiamine downregulated the expression of important regulatory proteins such as p-MEK and p-ERK, leading to the inhibition of Raf/MEK/ERK signalling pathways.

Conclusions: We found that Evodiamine exerts anticancer effects on osteosarcoma cells and has potential in the treatment of osteosarcoma.

MeSH Keywords: Apoptosis • Cell Cycle • Osteosarcoma

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/909682
Background

Osteosarcoma is one of the most prevalent types of bone tumors, mainly detected in adolescents and children. It has been reported that around 70% of osteosarcoma patients are ages 10–25 years [1]. The development of chemoresistance among osteosarcoma patients forms a bottleneck in the treatment of osteosarcoma [2]. Although the treatment strategies for osteosarcoma have improved, exploration of novel and efficient molecules is required to combat the development of drug resistance and to prevent osteosarcoma metastasis [3]. Consequently, new molecules are being screened for their anticancer activity against osteosarcoma. In the present study, we evaluated the anticancer activity of Evodiamine against the U2OS osteosarcoma cell line and in normal bone cells. Chemically, Evodiamine is an alkaloid that is generally isolated from *Evodia rutaecarpa* [4]. Many biological activities have been attributed to this naturally occurring molecule. These bioactivities include, but are not limited to, anti-inflammatory and anticancer activities [5, 6]. Several studies on Evodiamine have reported its anticancer activity. For instance, Evodiamine has been reported to inhibit the metastasis of lung and colon cancer cells [7]. Evodiamine has also been reported to exert antiproliferative effects on drug-resistant breast cancer cells [8]. The present study is the first to report the anticancer activity of Evodiamine against osteosarcoma cells, showing that Evodiamine exerts dose-dependent anticancer effects on U2OS osteosarcoma cells with no or minor effects on the growth of normal bone cells. Investigation of the underlying mechanisms revealed that Evodiamine triggers apoptosis in osteosarcoma U2OS cells, which was also associated with altered expression of apoptosis-related proteins. Furthermore, Evodiamine can prompt G2/M cell cycle arrest and inhibit the migration and invasion of U2OS cells. The Ras/MEK/ERK signalling pathway has been reported to be activated in several types of cancer cells [9]. In this study we observed that Evodiamine inhibited this pathway, indicating that Evodiamine may be an important lead molecule for the treatment of osteosarcoma.

Material and Methods

Cell lines and culture conditions

All chemicals and reagents were obtained from Santa Cruz biotechnology unless indicated otherwise. Evodiamine (98% purity by HPLC) was obtained from Sigma-Aldrich. Osteosarcoma U2OS cell line and normal bone cells were procured from the American Type Culture Collection. The cell lines were maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, antibiotics (100 units/mL penicillin and 100 µg/mL streptomycin), and 2 mM glutamine. The cells were cultured in an incubator (Thermo Scientific) at 37°C with 98% humidity and 5% CO₂.

Cell viability assay

Osteosarcoma cell viability was determined by MTT assay. In brief, the cultured U2OS osteosarcoma cells were seeded at the density of 1.5×10⁴ in 96-well microtiter plates and cultured for 24 h at 37°C. This was followed by the addition of MTT solution in all the wells and then the absorbance at 570 nm was assessed using an ELISA plate reader.

Apoptosis assay

The osteosarcoma U2OS cells were seeded in 6-well plates (2×10⁴ cells per well) and cultured at 37°C for 24 h. The cells were then stained with DAPI to detect the apoptosis by fluorescence microscopy, as previously reported [10]. To determine the percentage of apoptotic cells, an FITC-Annexin V/PI Apoptosis detection kit was used according to the instructions of the manufacturer.

Cell cycle analysis

The distribution of the U2OS cells in various phases of the cell cycle was assessed by flow cytometry. Briefly, 0, 3, 6, and 12 µM of Evodiamine-treated U2OS cells were cultured after 24 h of culturing at 37°C and subjected to washing with PBS. The U2OS cells were then fixed with ethanol (70%) for about 1 h and then again subjected to washing with PBS. The cells were finally resuspended in solution of PI (50 µl/ml) and RNase1 (250 µg/ml). This was followed by incubation for 30 min at room temperature and a final investigation under a fluorescence-activated cell-sorting cater-plus cytometer using 10 000 cells/group. The estimation of the percentage of cells in each phase of the cell cycle done using WinMDI software.

Cell migration and invasion assay

The cell migration of the osteosarcoma U2OS cells was determined by wound-healing assay. After culturing for 24 h at 37°C, the media and the cells were subjected to PBS washing. Thereafter, a wound was scratched using a sterile pipette tip and photographed. The cells were then grown for another 24 h and a photograph was taken again. Cell invasion of the Evodiamine-treated cells was performed by Transwell assay. Briefly, the U2OS cells were cultured at 2×10⁴ cells/mL density followed by the addition of 200 mL of these cultured cell suspensions to the upper chamber and whole medium was added into the bottom wells. The cells were cultured for 24 h at 37°C. The U2OS cells that migrated through the chambers were subjected to fixation with methyl alcohol followed by crystal violet staining. Finally, an inverted microscope was used to count cells (200×, 10 different fields).
To analyze expression of proteins (Cytochrome c, Bax, Bid, Caspase 3, 9, 8, PARP, cyclin B1, Cdc25c, Cdc2, MEK, and ERK), the osteosarcoma cells were lysed and the proteins were extracted. The proteins in each sample were then quantified by BCA assay and Western blotting was carried out, as described previously [11].

**Western blotting**

To analyze expression of proteins (Cytochrome c, Bax, Bid, Caspase 3, 9, 8, PARP, cyclin B1, Cdc25c, Cdc2, MEK, and ERK), the osteosarcoma cells were lysed and the proteins were extracted. The proteins in each sample were then quantified by BCA assay and Western blotting was carried out, as described previously [11].

**Statistical analysis**

The experiments were carried out in triplicate and the values represent means of the 3 replicates ± SD. The t test was used for statistical analysis using GraphPad Prism 7 software. The values were considered significant at $p<0.05$. 
Results

Evodiamine inhibits the growth of osteosarcoma cells via induction of apoptosis

The antiproliferative activity of Evodiamine was evaluated against U2OS osteosarcoma cell line and normal hFOB 1.19 cells. The results revealed that Evodiamine significantly ($p < 0.05$) inhibited the proliferation of U2OS osteosarcoma cell line with IC$_{50}$ of 6 µM. However, Evodiamine exhibited mild antiproliferative effects on the normal hFOB 1.19 cells with an IC$_{50}$ of 105 µM (Figure 1A).

The morphological analysis of the Evodiamine-treated cells showed blebbing and shrinkage, which are characteristic of apoptosis (Figure 1B). Consistent with the above results, DAPI and annexin V/PI staining showed that Evodiamine triggered apoptosis in U2OS cells and the percentage of the apoptotic cells was significantly enhanced ($p < 0.05$) with increasing concentrations of Evodiamine (Figure 2A, 2B). Apoptosis is associated with altered expression of several proteins; therefore, we examined the expression of cytochrome c, Bax, Bid, Caspase 3, 9, and 8, and PARP. The results revealed that Evodiamine treatment upregulated the expression levels of cytosolic cytochrome c, mitochondrial...
Bax, cleaved caspase 3 and 9, and PARP (Figure 3). Taken together, these results clearly show that the antiproliferative effects of Evodiamine are at least in part due to induction of apoptosis.

Evodiamine triggers G2/M cell cycle arrest in osteosarcoma cells

We also investigated whether Evodiamine triggers G2/M cell cycle arrest in U2OS osteosarcoma cells. The results showed that Evodiamine significantly ($p<0.05$) increases the percentage of cells in G2 phase of the cell cycle in a concentration-dependent manner (Figure 4). Moreover, protein expression analysis of cell cycle regulatory proteins revealed that Evodiamine caused significant downregulation of cyclin B1, Cdc25c, and Cdc2, as well as their phosphorylated counterparts (Figure 5).

Evodiamine inhibits cell migration and invasion of osteosarcoma cells

Next, the effect of Evodiamine on the migration and invasion of the U2OS cancer cells was investigated by wound-healing and Transwell assays. We found that at IC$_{50}$, Evodiamine significantly ($p<0.05$) inhibited the migration and invasion of U2OS osteosarcoma cells (Figure 6A, 6B). Suppression of cell migration was also associated with inhibition of expression of metalloproteinases (MMP) 2 and 9 (Figure 6C).

Evodiamine inhibits the Raf/MEK/ERK signalling pathway of osteosarcoma cells

The effect of Evodiamine on the Raf/MEK/ERK signalling cascade was also examined. We found that Evodiamine significantly ($p<0.05$) suppressed the expression of p-MEK and p-ERK in a dose-dependent manner, while no effect was found on MEK and ERK protein expression (Figure 7).

Figure 5. Western blots showing the effect of Evodiamine on the expression of cell cycle-related proteins. The experiments were carried out in triplicate.

Figure 6. Inhibition of (A) cell migration (B) cell invasion of U2OS cells treated with Evodiamine at IC$_{50}$ concentration. (C) Western blots showing the effect of Evodiamine on the expression of MMP-2 and MMP-9. The experiments were carried out in triplicate.
Evodiamine induces apoptosis, G2/M cell cycle arrest…
© Med Sci Monit, 2018; 24: 5874-5880

Discussion

Plants are natural chemical factories producing a wide diversity of chemical scaffolds. The metabolites are produced by plants as a defense against the biotic and abiotic stresses [12]. Since plants are often exposed to extreme environmental conditions, they have evolved to produce different types of secondary metabolites. These metabolites have been shown to be beneficial in the treatment of human diseases [13]. Evodiamine is an important plant-derived alkaloid that has been reported to inhibit the growth of cancer cells [14,15]. However, the anti-cancer activity of Evodiamine has not been evaluated against osteosarcoma. Given this background, we examined the antiproliferative effects of osteosarcoma against a panel of osteosarcoma cell lines. We found that Evodiamine inhibited the proliferation of the U2OS osteosarcoma cells with an IC50 of 6 µM. Evodiamine was also previously reported to inhibit the growth of colon cancer, breast cancer, and hepatocellular carcinoma cells [6,16]. The morphological examination of Evodiamine-treated cells showed shrinkage and blebbing, which are characteristic of apoptosis, and this motivated us to investigate whether Evodiamine inhibits cell proliferation by triggering apoptosis. Apoptosis is an important and highly conserved type of cell death that is considered imperative for normal developmental processes, host defense, and inhibition of oncogenesis [17]. Deregulated apoptosis is a characteristic of cancer cells, and molecules that stimulate apoptosis in cancer cells may prove beneficial in the development anticancer chemotherapy [18]. Interestingly, in the present study, Evodiamine did induce apoptosis in U2OS osteosarcoma cells. It is well established that upregulation of Bax and downregulation of Bcl-2 makes the outer membrane of the mitochondria more porous and thereby facilitates the release of some mitochondrial apoptotic proteins, which ultimately cause the activation of caspases [19]. In the present study, we observed that the expression of cyto c, Bax, cleaved caspase 3 and 9, and cleaved PARP was significantly increased, indicative of intrinsic apoptosis. However, no effect was observed on the expression of caspase 8, thereby ruling out the possibility of the intrinsic apoptosis. Analysis of the Evodiamine-treated U2OS cells at different phases of the cell cycle indicated that Evodiamine prompts G2/M cell cycle arrest. Cell cycle in eukaryotes is generally driven by the stimulation of cyclin-dependent kinases and their cofactor, cyclin [20]. In the present study, we observed that Evodiamine caused a significant decrease in the expression of cyclin B1, Cdc25c, and Cdc2, favoring cell cycle arrest at G2/M phase. Metastasis of osteosarcoma is very challenging to manage; therefore, it is important to discover molecules that can inhibit the metastasis of osteosarcoma cells [21]. In the present study, we observed that Evodiamine inhibited the migration and invasion of U2OS osteosarcoma cells. Dysregulation of the RAS/extracellular signal-regulated kinase (ERK) pathway is common in cancer cells; therefore, targeting this pathway may provide a novel alternative to conventional therapy [9,22]. We examined the effect of Evodiamine on the RAF/MEK/ERK pathway and found that Evodiamine prevented the phosphorylation of MEK and ERK, suggesting that Evodiamine is a potential candidate to target this pathway.

Conclusions

We found that Evodiamine may be an important molecule for the treatment of osteosarcoma. Evodiamine inhibits the proliferation of osteosarcoma cells by induction of apoptosis and cell cycle arrest and warrants further in vivo studies.

References:

1. Li X, Jiang H, Xiao L et al: miR-200bc/429 inhibits osteosarcoma cell proliferation and invasion by targeting PMP22. Med Sci Monit, 2017;23: 1001–8
2. Wu G, Liang Q, Liu Y: Primary osteosarcoma of frontal bone: A case report and review of literature. Medicine, 2017; 96: e9392
3. Ługowska I, Plenkowski A, Szumera-Ciećkiewicz A et al: [The long-term treatment outcomes of adult osteosarcoma.] Pol Merkur Lekarski, 2017; 42(250): 158-64 [in Polish]
4. Jiang J, Hu C: Evodiamine: A novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules, 2009; 14: 1852–59
5. Choi YH, Shin EM, Kim YS et al: Anti-inflammatory principles from the fruits of Evodia rutaecarpa and their cellular action mechanisms. Arch Pharmacal Res 2006; 29: 293–97
6. Fei XF, Wang BX, Li Ti et al: Evodiamine, a constituent of Evodiae fructus, induces anti-proliferating effects in tumor cells. Cancer Sci, 2003; 94: 92–98
7. Kan SF, Yu CH, Pu HF et al: Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J Cellu Biochem, 2007; 101: 44–56
8. Du J, Wang XF, Zhou QM et al: Evodiamine induces apoptosis and inhibits metastasis in MDA MB-231 human breast cancer cells in vitro and in vivo. Oncology Rep, 2013; 30: 685–94
9. Shimizu T, Tolcher AW, Papadopoulos KP et al: The clinical effect of the dual-targeting strategy involving PI3K/akt/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res, 2012; 18: 2316–25
10. Sarosiek KA, Fraser C, Muthalagu N et al: Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics. Cancer Cell, 2017;31: 142–56
11. Du L, Fei Z, Song S, Wei N: Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio. Biomed Pharmacotherap, 2017; 95: 447–52
12. Kim JB, Yu JH, Ko E et al: The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomed, 2010; 17: 436–40
13. Harrison DI, Geller DS, Gill ID et al: Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther, 2018; 18: 39–50
14. Liao CH, Pan SL, Guh JH et al: Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis, 2005; 26: 968–75
15. Kan SF, Huang WJ, Lin LC, Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer, 2004; 110: 641–51
16. Wang S, Wang L, Shi Z et al: Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. PLoS One, 2014; 9: e97512
17. Llambi F, Green DR: Apoptosis and oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet Dev, 2011; 21: 12–20
18. Zakrzewski O, Marcinkiewicz C, Aloui Z et al: Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression. Mol Carcinog, 2017; 56: 18–35
19. Huysmans M, Lema S, Coll NS, Nowack MK: Dying two deaths – programmed cell death regulation in development and disease. Curr Opin Plant Biol, 2017; 35: 37–44
20. Yao R, Han D, Sun X et al: Scriptaid inhibits cell survival, cell cycle and promotes apoptosis in multiple myeloma via epigenetic regulation of p21. Exp Hematol, 2018; 2: 55–63
21. Sundara YT, Kostine M, Cleven AH, Bovée JV et al: Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: A rationale for T-cell-based immunotherapy. Cancer Immunol Immunother, 2017; 66: 119–28
22. Steelman LS, Franklin RA, Abrams SL et al: Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011; 25: 1080–87